Bayer appointment
This article was originally published in The Tan Sheet
Executive Summary
Barbara Korberly named VP-clinical research & medical affairs activities for the Morristown, N.J.-based R&D unit, Bayer Consumer Care announces April 14. She also will lead the firm's aspirin cardio-prevention projects; Bayer recently filed a citizen petition with the FDA requesting clearance to label aspirin with claims for primary prevention of myocardial infarction (1"The Tan Sheet" Feb. 17, 2003, p. 3). Korberly joins Bayer from Pharmacia, where she served as head of global medical...
You may also be interested in...
Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition
Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.